Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
6
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
6
×
san diego top stories
6
×
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
6
×
wisconsin blog main
wisconsin top stories
ipo
novartis
cancer
clinical trials
eli lilly
teva pharmaceutical
amgen
asklepios biopharmaceutical
biogen
calcitonin gene-related peptide
cancer immunotherapy
crispr
What
new
6
×
bio
fda
ipo
roundup
approval
class
companies
drug
drugs
life
medicines
migraine
million
science
therapeutics
won
activity
allogene
amgen
approvals
arguments
bails
big
biogen
biotechs
brand
bridgebio
cancer
candidates
capital
car
clamped
club
commercialized
competitors
continued
covid
crispr
crop
Language
unset
Current search:
fda
×
biotech
×
" san diego top stories "
×
" san diego blog main "
×
" texas top stories "
×
new
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines